Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

Scott Eggener, MD, associate professor of surgery, co-director, Prostate Cancer Program, director, Transitional and Outcomes Research, Section of Urology, The University of Chicago Medicine, discusses screening for prostate cancer.

Douglas M. Dahl, MD, FACS, discusses the long-term results of post-prostatectomy radiotherapy.

Abiraterone acetate in combination with low-dose prednisone (5 mg) significantly lowered PSA levels with a consistent toxicity profile in men with high-risk nonmetastatic castration-resistant prostate cancer.

Multiparametric MRI following a suggestive PSA test or digital rectal exam resulted in a 73% reduction in the need for biopsy.

The role of androgen receptor variant-7 in patients with early stage prostate cancer is not well characterized but data presented at the 2015 American Urological Association Meeting by Tyler M. Bauman, BS, is bringing the discussion into focus.

Leonard Gomella, MD, professor, Jefferson University, physician, chair, Department of Urology, director, Kimmel Cancer Center Network, discusses results from a study that assessed the corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer (mCRPC).

PSA testing utilization decreased by 50% among primary care physicians at Oregon Health & Science University, following a recommendation against screening from the USPSTF.

An exosomal messenger RNA-based urine diagnostic demonstrated high negative predictive value for high-grade prostate cancer.

Ryan Werntz, MD, urologist, Oregon Health and Science University, discusses a study which examined trends in prostate-specific antigen (PSA) utilization in primary care physicians.

Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine, discusses the potential of AR-V7 as a biomarker in early stage castration-resistant prostate cancer (CRPC).

Enzalutamide significantly improved progression-free survival and PSA progression compared with bicalutamide in men with metastatic and non-metastatic castration-resistant prostate cancer.